1. Impact of catheter ablation for atrial fibrillation on cardiac disorders in patients with coexisting heart failure
- Author
-
Koh Ono, Takeshi Kimura, Masashi Kato, Satoshi Shizuta, Shintaro Yamagami, Tetsuma Kawaji, Takafumi Yokomatsu, Shinji Miki, and Takanori Aizawa
- Subjects
lcsh:Diseases of the circulatory (Cardiovascular) system ,medicine.medical_specialty ,Systolic dysfunction ,medicine.drug_class ,medicine.medical_treatment ,Diastole ,Heart failure ,Catheter ablation ,030204 cardiovascular system & hematology ,Ventricular Function, Left ,03 medical and health sciences ,0302 clinical medicine ,Original Research Articles ,Internal medicine ,Natriuretic peptide ,medicine ,Humans ,Cumulative incidence ,Original Research Article ,cardiovascular diseases ,030212 general & internal medicine ,Ejection fraction ,business.industry ,Stroke Volume ,Atrial fibrillation ,medicine.disease ,Treatment Outcome ,lcsh:RC666-701 ,cardiovascular system ,Cardiology ,Ventricular pressure ,Diastolic dysfunction ,Cardiology and Cardiovascular Medicine ,business - Abstract
Aims We sought to investigate the time course of cardiac disorders after catheter ablation for atrial fibrillation (AF) in patients with coexisting heart failure (HF) during long‐term follow‐up. Methods and results We analysed consecutive 280 patients undergoing first‐time catheter ablation for AF who had coexisting HF, which was defined as prior HF hospitalization, estimated right ventricular systolic pressure ≥45 mmHg, or B‐type natriuretic peptide (BNP) ≥200 pg/dL before the procedure. The primary endpoints were improvements in left ventricular ejection fraction (LVEF), E/e′, BNP, left atrial dimension (LAD), and mitral regurgitation (MR) at 1 year. The secondary endpoints were serial changes of LVEF, E/e′, BNP, LAD, and MR at 6 months, 1 year, and 5 years and cumulative incidence of HF hospitalization. During the mean follow‐up of 5.1 ± 3.0 years, 70.7% of patients were free from recurrent AF. Among patients with LVEF
- Published
- 2020